Mangoceuticals Reports Q1 Loss Amid Revenue Decline and Rising Operational Costs

Mangoceuticals, Inc. (NASDAQ: MGRX)

Company Overview:
Mangoceuticals, Inc. focuses on men’s wellness products delivered through a telemedicine platform, including brands targeting erectile dysfunction and hair loss. The company is conducting clinical trials for respiratory illness prevention technology and has established master distribution agreements for various formulations.

Recent Financial Performance (Q1 2025):

• Revenues: $109,306 (down from $214,095 in Q1 2024).
• Cost of Revenues: Increased to $47,242, primarily due to service fluctuations.
• Gross Profit: $62,064 (down from $147,398 in Q1 2024).
• Operating Expenses: $4,915,253 (up from $2,515,015 in Q1 2024), driven by legal matters and tech development.
• Net Loss: $4,839,489 (compared to a net loss of $2,367,617 in Q1 2024).
• Basic and Diluted Loss Per Share: $(1.29) (compared to $(1.50) in Q1 2024).

Positive Aspects:

• Increased cash reserves to $76,496 (up from $58,653 as of December 31, 2024).
• Continued commitment to clinical trials and expanding product lines under development agreements.
• Solid progress in raising capital through various financing activities.

Negative Aspects:

• Significant net loss indicates ongoing operational inefficiencies and a need for more strategic management of expenses.
• Decrease in revenue signals potential challenges in customer retention or market shifts.
• Heightened legal expenses and settlements may continue to impact overall financial health.

Key Statistics:
- Gross Margin: 56.8%
- Cash Balance: $76,496
- Total Liabilities: $1,503,196
- Accumulated Deficit: $25,939,986

Future Outlook:
Mangoceuticals aims to continue leveraging its telemedicine platform and product range while addressing its funding needs. The company plans to conduct further capital raises and explore strategic alternatives to bolster growth and financial stability. Potential risks include the need for regulatory approvals and competition within the rapidly evolving health tech sector.